Menu
Search
|

Menu

Close
X

Spectrum Pharmaceuticals Inc SPPI.OQ (NASDAQ Stock Exchange Global Select Market)

20.46 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 20.46
Open --
Volume --
3m Avg Volume 454,815
Today’s High --
Today’s Low --
52 Week High 23.50
52 Week Low 5.47
Shares Outstanding (mil) 93.94
Market Capitalization (mil) 1,341.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
63
FY16
146
FY15
163
EPS (USD)
FY17
-0.553
FY16
-0.935
FY15
-0.780
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
10.16
5.77
Price to Book (MRQ)
vs sector
5.84
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
50.39
16.52
LT Debt to Equity (MRQ)
vs sector
50.39
12.22
Return on Investment (TTM)
vs sector
-22.34
14.43
Return on Equity (TTM)
vs sector
-36.04
16.13

EXECUTIVE LEADERSHIP

Stuart Krassner
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Joseph Turgeon
President, Chief Executive Officer, Director, Since 2017
Salary: $593,750.00
Bonus: $345,000.00
Kurt Gustafson
Chief Financial Officer, Executive Vice President, Since 2013
Salary: $492,500.00
Bonus: $235,000.00
Thomas Riga
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Luigi Lenaz
Lead Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11500 S Eastern Ave Ste 240
HENDERSON   NV   89052-5576

Phone: +1702.8356300

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

SPONSORED STORIES